Nutcracker Therapeutics Named Industry Veteran Samuel Deutsch as Chief Scientific Officer

EMERYVILLE, Calif.–(BUSINESS WIRE)–Dr. Deutsch’s appointment starts off pivotal year for the company, in which lead mRNA drug candidate, NTX-250, will enter clinical trials.
Click here to view original post